HCC: IMbrave150

Xiao-Qian Xu1,2, Wei-Ming Li1,2, Li-Chen Shi1,2

  • 1National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

The oncologist
|September 2, 2025
PubMed
まとめ

アテゾリズマブ (Atez) とベバシズマブ (Bev) を一時的に中止すると,切除できない肝細胞癌 (HCC) の生存結果は悪化しなかった. この発見は,治療中断が安全である可能性を示唆し,さらなる調査が必要である.

関連する概念動画

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448